NORTON META TAG

16 November 2020

As U.S. Faces Out-of-Control Pandemic, Pfizer Raises Hope for Vaccine, But Many Questions Remain & Trump Lies About COVID-19 Risks & Vaccine at Debate as Pandemic Is Tied to 300K Excess U.S. Deaths10NOV&23OKT20

PHYSICAL DISTANCING: SIX FEET APART IS BETTER THAN SIX FEET UNDER!

Coronavirus Updates

John Hopkins Univ Coronavirus Covid-19 Dashboard


Avi Schiffmann CORONAVIRUS DASHBOARD

 THIS is fantastic news from Pfizer but it does not mean the end of the coronavirus Covid-19 pandemic. Much more testing needs to be done and there are more vaccines in the works. I love the fact that the Pfizer senior VP and head of vaccine research Kathrin Jansen refutes lying (NOT MY) vice-pres pence's claim that (NOT MY) pres drumpf's / trump's administration and "operation warp speed" had nothing to do with the funding of Pfizer's research and contributed nothing to Pfizer's development of their vaccine. I also love how Laurie Garrett does not hesitate to correct Amy Goodman on air for repeating falsehoods regarding Pfizer's testing of their vaccine. Democracy Now! has had Laurie Garrett on many times and I have always appreciated her honest and straightforward interviews and appreciate her opinions on the pandemic and vaccine development in this piece. This is followed  by the Democracy Now! interview of Dr Ali Khan on the state of the coronavirus Covid-19 pandemic in America because of (NOT MY) pres drumpf's / trump's, (NOT MY) vice-pres pence's, their administration's and the republican party's lies and inaction.

As U.S. Faces Out-of-Control Pandemic, Pfizer Raises Hope for Vaccine, But Many Questions Remain

STORYNOVEMBER 10, 2020

Pharmaceutical giant Pfizer has announced that a Phase 3, late-stage study found their potential COVID-19 vaccine showed more than 90% effectiveness. The two-dose vaccine still faces several challenges, including how to store and transport it, since it must be refrigerated at subzero temperatures. Pulitzer Prize-winning science journalist Laurie Garrett says the news is hopeful, but urges caution. “There’s been no scientific release. There’s no published data,” she says. “We don’t have anything to go with except what the lawyers at Pfizer massaged carefully into a single-page press release. So, we have to take that with a big caveat.”


As U.S. Faces Out-of-Control Pandemic, Pfizer Raises Hope for Vaccine, But Many Questions Remain

GUESTS
  • Laurie Garrett
    Pulitzer Prize-winning science writer and former senior fellow for global health at the Council on Foreign Relations.

Transcript
This is a rush transcript. Copy may not be in its final form.

AMY GOODMAN: As the number of coronavirus cases worldwide tops more than 51 million, the U.S. pharmaceutical company Pfizer announced Monday a Phase 3, late-stage study found their potential COVID-19 vaccine shows more than 90% effectiveness. This is Pfizer CEO Albert Bourla on CNN.

ALBERT BOURLA: Ninety percent is a game changer. Ninety percent, now you are hoping to have a tool in your war against this pandemic that could be significantly effective. How long this protection will last is something that we don’t know right now. … We believe that we are in a good situation to have up to 50 million doses this year globally. And I believe we are in a very, very good situation to have 1.3 billion doses globally.

AMY GOODMAN: The two-dose vaccine still faces several challenges, including how to store and transport it, since it must be refrigerated at subzero temperatures.

In response to the news, Vice President Mike Pence tweeted, ”HUGE NEWS: Thanks to the public-private partnership forged by President @realDonaldTrump, @pfizer announced its Coronavirus Vaccine trial is EFFECTIVE, preventing infection in 90% of its volunteers,” unquote. Pfizer immediately debunked the claim, which referenced Operation Warp Speed, the federal effort to rush a vaccine to market. Senior vice president and head of vaccine research, Kathrin Jansen, told The New York Times, quote, “We were never part of the Warp Speed. … We have never taken any money from the U.S. government, or from anyone,” she said.

Meanwhile, President-elect Joe Biden said Monday the coronavirus vaccine approval process must be guided by science, and warned a vaccine likely won’t be available for months. He spoke after meeting with the 12-member coronavirus task force that he has just appointed to advise him during the transition before his January 20th inauguration. It includes Dr. Rick Bright, the whistleblower from the Trump administration who said his early warnings about the pandemic were ignored.

PRESIDENT-ELECT JOE BIDEN: This group will advise on detailed plans built on a bedrock of science, and the key compassion, empathy and care for every American at its core, making rapid testing widely available — more widely available, much more widely available — and building a core of contact tracers who will track and curb this disease, while we prioritize getting vaccines first to the most at-risk populations.

AMY GOODMAN: President-elect Biden has also said he plans to repair the U.S. relationship with the World Health Organization. This comes as the U.S. passed 10 million COVID cases on Monday, with the most recent 1 million infections happening faster than any previous million — in just 10 days.

Well, for more, we’re joined by Laurie Garrett, Pulitzer Prize-winning science writer, former senior fellow for global health at the Council on Foreign Relations. She’s the author of a number of books, including Ebola: Story of an Outbreak and The Coming Plague: Newly Emerging Diseases in a World Out of Balance.

It’s great to have you with us, Laurie. Thanks so much for joining us. If you can first start off by responding to the Pfizer announcement yesterday?

LAURIE GARRETT: Well, on the front end, I have to say it’s great news. It’s always encouraging to see positive results in a vaccine trial, especially at this stage in an epidemic, very quickly. And, you know, it’s hopeful. But it is only a press release. There has been no scientific release. There’s no published data. We don’t have anything to go with except what the lawyers at Pfizer massaged carefully into a single-page press release. So, we have to take that with a big caveat.

And the other thing that has to be considered very carefully is that this president is in the process of carrying out retribution, vindictive firings all across his government, getting rid of people who have stood up to him in various agencies. I mean, the most astounding was yesterday, firing the secretary of defense. And Steve Hahn, the head of FDA, has been consistently on Trump’s hit list. He stood up to the president regarding hydroxychloroquine, regarding convalescent plasma therapy and other things that the president claimed would treat or cure or eliminate COVID, but they wouldn’t. And so, we could have a situation now where, in the coming days, Steve Hahn’s head would go on a platter, and the FDA would really not be able to take speedy steps to usher this vaccine through the next stage that could allow it to potentially get an emergency approval before the new year.

AMY GOODMAN: Laurie Garrett, just very quickly, explain what you mean by Esper — the significance of him in relation to the vaccine. He is in charge of Operation Warp Speed? He’s the secretary of defense.

LAURIE GARRETT: No, my reason for raising that is that it’s very clear the president has now offed, by my count, 10 people in the government, from USAID, from the Energy Commission, from all sorts of different agencies and departments around the government. If he targets Steve Hahn, as he has threatened to do many times — he has threatened Steve Hahn, the FDA commissioner, with firing on multiple occasions. If he offs him, it would be very hard to imagine how the FDA could proceed for a rapid approval of this vaccine.

Meanwhile, I mean, there are issues about the vaccine. Because of the nature of how the Operation Warp Speed trial designs were set up, it is possible to claim victory based on seven days of data. And that’s what this study did. They had two arms of volunteers — one were placebo recipients, one were vaccine recipients. The two arms are blinded, so none of the people executing the study know who is getting what. And that’s good, and that’s how it should be. And one arm had eight cases, and the other arm had 80 cases. And that looks like, since the arm with the eight cases was the vaccine recipient arm, then that gives it what they call 90% effectiveness in protecting against infection. But the window of looking at these people to see did they get coronavirus infected was seven days, seven days after their booster shot. Well, you know, that’s a pretty short-term durability of immune response. And if eight people got infected in just seven days, I wonder what the infection rate and the protection rate of this vaccine would be if you were looking out over two months.

JUAN GONZÁLEZ: And, Laurie, what do we know about the trial participants? There was supposedly, I think, 44,000 of them. Do we know anything about the breakdown in terms of vulnerable populations or not, or different nationalities? What do we know?

LAURIE GARRETT: Actually, we know a great deal, and all of this was in the press release detailed — far more detail about that than the outcome of the research. And, yes, it’s very, very racially diverse, age diverse. There are healthcare workers that are very directly exposed. It actually, you know, on the face of it, looks like an excellent study panel.

JUAN GONZÁLEZ: And in terms of the capacity of Pfizer and BioNTech to produce 50 million doses of the vaccine this year and 1.3 billion, as they claim, in 2021, has the U.S. already purchased some of these in advance? What’s the situation in terms of the rollout, if it is approved, especially to vulnerable populations? Do we have any idea about that?

LAURIE GARRETT: One of the key features of Operation Warp Speed on the U.S. side, and its equivalent efforts all over the world in wealthy countries, and in WHO’s hands, is to try and encourage drug companies to go ahead and gear up for manufacturing even before the trial results are in, so that we don’t — precisely to your point, we didn’t want to feet dragging, waiting for production capacity to rev up. Instead, everybody has been encouraged to gamble — and it’s a big financial gamble — to gamble that their vaccine will indeed work and to build up production capacity right away.

And so, Pfizer claims that they already have production capacity to make tens of millions of doses and that they will be revved up to make billions of doses sometime in late 2021. But at the front end, keep in mind, when you hear a figure like 50 million doses available, everybody has to take two. So that’s actually 25 million human beings vaccinated, not 50 million. And that means that there has to be determination of who gets in the front of the line and who gets in the second tier of the line. And the National Academy of Medicine has held numerous hearings on this topic to try and come up with equitable, smart ways to decide, essentially, who goes first. And obviously, frontline healthcare workers are at the front of that line.

AMY GOODMAN: And can you talk about the significance not only of the two-shot vaccine, but of it having to be kept at subfreezing temperature — states across the country are asking how exactly are they going to be dealing with this — not only what this means in the United States, but around the world, especially in poorer countries?

LAURIE GARRETT: Well, I’ve detailed a lot of this in a piece that’s published today by Foreign Policy, so people can look at that and see some of the — more references to things I’m going to say now. The first thing I really want to underscore is, the Pfizer vaccine may be the first one we’re hearing about, but there are a lot of other ones, more than 200 in the pipeline. And many of them will in fact be better vaccines, will have even better results and will be easier to transport, easier to store, easier — perhaps require only one dose, and so on. So, you know, let’s not put all of our eggs in this particular basket.

But it is based on nucleic acid. It’s made from mRNA, messenger RNA. And this is the molecule that carries the blueprint from the DNA — right? — to the machinery inside the cell that manufactures proteins. And so, what it’s doing is turning your cells, your human cells, into little factories to make the protein that’s on the outside, that sticks up on the outside, in multiple copies surrounding the virus. And that way, making just that protein, which is harmless, your immune system will see it and make antibodies against it. So it’s programming your immune system to recognize the enemy.

The problem is that that mRNA is very unstable. It is so unstable that it has to be stored at minus-100 degrees Fahrenheit. Some reports say -110 degrees Fahrenheit, which is well below anybody’s freezer capacities. And so, you either have to have very, very, very powerful freezers or a lot of dry ice. And there we get to the second part of the problem. It’s been pointed out repeatedly that we have a global shortage of dry ice. Dry ice has to be made from pure CO2, and the primary source of pure CO2 in the whole sort of manufacturing chain for dry ice is burning ethanol. And since the epidemic has resulted in a huge decrease in the burning of fossil fuels, it’s also, fortunately, resulted in a decrease in the emission of CO2, including into this pure form to make dry ice.

So, all sorts of steps in the chain of transport and use of this vaccine will be challenging. And this was pointed out by the National Governors Association in a very blistering letter that they sent formally to Robert Redfield, the head of the CDC, and to the White House, saying, “You’re asking us, as governors, to be prepared to do mass immunization of our populations without telling us details about the likely vaccine. But we understand that at the front of the line are vaccines that require deep, deep, deep, deep, deep ultra freezing. We don’t have deep, deep, deep, deep ultra freezers. Our health departments are woefully underfunded. We don’t have the capacity to do this. Where will the money come from? Where will the equipment come from? Who’s in charge of all of this? And how are we going to do this?” And the response from the White House so far was simply to say, “Hey, you know, you should have been at this meeting, because we talked about that at this meeting. And Governor Cuomo, the head of the National Governors Association, didn’t show up for the meeting.”

JUAN GONZÁLEZ: And, Laurie, what do you make of the timing of this announcement coming just a couple of days after Joe Biden was declared the winner of the presidential debates? There’s, rightfully, some questions asked as to whether Pfizer and BioNTech could have made this announcement one or two days earlier or a week earlier? What’s your sense?

LAURIE GARRETT: The CEO of Pfizer made it very clear, in multiple public appearances and in writing, more than three weeks ago, that he was not going to see his vaccine be a political football, that he wasn’t making guarantees to have it available by any deadline date that was set by the White House or by anybody else, but that the science would determine, he said, what date the information, the results would be released. And we just have to take his word for it.

AMY GOODMAN: I wanted to ask you about Public Citizen saying that Pfizer should not have released this by press release without being able to provide further data, the questions, Laurie, about who this was tested on. Health Research Group’s Michael Carome released this statement saying, quote — that statement said, quote — I’m going to go to it right now — “The release of preliminary and incomplete clinical trial data by press release to the public is bad science. Until the trial results are independently reviewed and scrutinized by staff at the U.S. Food and Drug Administration and the independent experts on the agency’s Vaccines and Related Biological Products Advisory Committee, enthusiasm for the apparently promising interim results announced by Pfizer and BioNTech must be tempered. Crucial information absent from the companies’ announcement is any evidence that the vaccine prevents serious COVID-19 cases or reduces hospitalizations and deaths due to the disease. More importantly, critical safety data from the phase 3 trial of the … vaccine is not yet available.” But who has been tested so far, I mean, who the trials have been conducted on, the concerns raised — in the United States, communities of color, Latinx and African American populations underrepresented in a lot of these vaccine trials, and Oxfam raising the concern the vaccine would be committed — Oxfam has said the vaccine would be, quote, “0% effective to the people who can’t access or afford it.”

LAURIE GARRETT: Well, there’s a lot of truth and untruth in that mix of comments that you just put out. First of all, Pfizer put out a very detailed list, as I already said to Juan, of the racial breakdown, age breakdown and susceptibility to COVID disease breakdown of the participants in their study. And it is a very diverse group. And I just — I don’t know who’s making claims otherwise, but they should look at the breakdown. It’s been published and known for quite some time.

But the larger question: What does this vaccine, or anything of its nature similar, like the Moderna vaccine, which is also based on mRNA and will require deep freezing, and some of the other vaccines in the pipeline that have difficult either production issues or logistic issues associated with the nature of the vaccine — what does this mean for the rest of the world? And that’s a very legitimate question and a very troubling one, but one that the community has been confronting from the very beginning. I mean, all the way back in February, there has been discussion of this.

COVAX was set up, which is a cooperative for vaccines, COVAX, set up by WHO in conjunction with several lead countries. Almost every country in the world is now a member — notably not the United States, because Trump refused to be involved in anything that WHO had its fingerprints on. But COVAX is a consortia of all the nations’ both producers of vaccines and likely recipients committing to lowering their patent thresholds, making vaccines affordable and available for the whole world, and trying to rush them into some form of generic manufacturing so that we’re not reliant on a single patent-based manufacturing site.

So, we’re learning from past experiences that we have to take innovative approaches to vaccine production, because, otherwise, it’s not available for the whole world. Nevertheless, if a vaccine as difficult to make and to maintain in stable form as this one, the Pfizer vaccine, is becomes something that we try to execute worldwide, there will be very, very significant hurdles to overcome, both in the distribution part and in the manufacturing side on a mass scale. So, I think a lot of us are really hoping that some of the more traditional types of vaccines, which are in the pipeline, which would be usable through systems already in existence for mass vaccination of children, will turn out to be successful and will eventually come forward for mass production.

JUAN GONZÁLEZ: And, Laurie, we’re in the midst now of the second surge, if in some places the third surge, in the numbers of coronavirus cases, and now President-elect Biden has named his coronavirus task force. How do you assess the task force that Biden has named? And what do you see as what should be the first, the key steps that that task force has to take?

LAURIE GARRETT: Yeah, Juan, I argue in today’s piece in Foreign Policy that, you know, it’s a fine task force — good names, smart people. And notably, exceptional differences compared to the current COVID task force in the White House, there are no relatives of the president-elect on the task force; there are no financial interests associated with the president-elect or his family or close associates represented on the task force. It is a public health and scientific task force. And I’m confident that they will make decisions based on the seven principles of fighting COVID, which the president-elect published on his website on Monday morning. And those clearly lay out a strategic scheme that’s in line with the kinds of things that Tony Fauci has been advocating and that most of the public health community has supported from the very beginning of this epidemic, that were never fully implement at any time, in any state, by any political leader in the United States of America, certainly not the president.

But let’s all be very clear. And this is the key point I really lead with in my Foreign Policy piece, is we are in very dire times in the United States right now. This surge that we’re in right now is going to surpass what we went through in the spring. We are looking very likely, because the administration will take no actions, to speak of, to control the spread of COVID for the next 70-plus days that Donald Trump is in charge of the country — we are looking very likely at 400,000 deaths cumulatively by Christmas. We will go to the inauguration with an out-of-control epidemic in all 50 states. It’s already out of control in 43 states. We will have surges that require actions by governors and mayors that exceed what most of them have ever done so far in fighting COVID. They’ll be very much like what we went through in New York in March, April and May. And the euphoria that we saw yesterday on the stock markets around the world in response to the Pfizer vaccine announcement will turn to a downturn as lockdowns are put in place, and we’ll feel more economic pain.

So, while I am optimistic that this COVID task force put together by President-elect Biden will take promising steps and certainly take this epidemic very, very, very seriously, both internationally, in the role of the United States as a world leader, and nationally, domestically, but there are 71 days left for this current president to screw up this epidemic further. He is a vindictive individual. He seems to be out of control right now in the White House. And I just — I’m terrified for what things he will and will not do between now and January 20th.

Trump Lies About COVID-19 Risks & Vaccine at Debate as Pandemic Is Tied to 300K Excess U.S. Deaths

STORYOCTOBER 23, 2020

President Donald Trump and former Vice President Joe Biden met in Nashville, Tennessee, on Thursday in the second and final debate of the 2020 campaign. It was a more subdued debate than their first clash, when Trump refused to abide by the rules and interrupted Biden at least 128 times. Thursday’s debate was moderated by NBC’s Kristen Welker, who began by asking the candidates about COVID-19. Biden criticized Trump for repeatedly downplaying the severity of the pandemic, while the president boasted about his handling of the crisis, falsely claiming a vaccine was “ready” to be deployed within weeks. Epidemiologist Dr. Ali Khan, dean of the College of Public Health at the University of Nebraska Medical Center and former director of the CDC’s Office of Public Health Preparedness and Response, says the political divide on how to deal with COVID-19 would be “unimaginable” for any other disease. He also says the Trump administration’s aims of reaching “herd immunity” by letting the virus run rampant in the U.S. is cruel and scientifically unsound. “That is the most unethical, disastrous approach possible,” he says.


Trump Lies About COVID-19 Risks & Vaccine at Debate as Pandemic Is Tied to 300K Excess U.S. Deaths

GUESTS
  • Dr. Ali Khan
    epidemiologist, dean of the College of Public Health at the University of Nebraska Medical Center, and former director of the CDC’s Office of Public Health Preparedness and Response.
Transcript
This is a rush transcript. Copy may not be in its final form.

AMY GOODMAN: As the U.S. death toll from COVID-19 tops 223,000, President Trump and former Vice President Joe Biden met in Nashville, Tennessee, Thursday in the second and final debate of the 2020 campaign. They sparred over the Trump administration’s response to the pandemic, healthcare, climate change, racism and U.S. immigration policy. Thursday’s matchup was originally scheduled to be the third and final debate, but Trump scuttled a second appearance earlier this month after refusing to take part remotely following his hospitalization with COVID-19.

Thursday’s debate was moderated by NBC’s Kristen Welker, who began by asking President Trump about his handling of the COVID-19 crisis. Trump praised his response while falsely claiming that 2.2. million people were expected to die, and falsely claiming a vaccine was, quote, “ready.”

PRESIDENT DONALD TRUMP: We have a vaccine that’s coming. It’s ready. It’s going to be announced within weeks, and it’s going to be delivered. We have Operation Warp Speed, which is — the military is going to distribute the vaccine.

I can tell you from personal experience that I was in the hospital, I had it, and I got better. And I will tell you that I had something that they gave me, a therapeutic, I guess they would call it. Some people could say it was a cure. But I was in for a short period of time, and I got better very fast, or I wouldn’t be here tonight. And now they say I’m immune. Whether it’s four months or a lifetime, nobody has been able to say that, but I’m immune. More and more people are getting better.

We have a problem that’s a worldwide problem. This is a worldwide problem. But I’ve been congratulated by the heads of many countries on what we’ve been able to do with the — if you take a look at what we’ve done in terms of goggles and masks and gowns and everything else, and in particular ventilators. We’re now making ventilators all over the world, thousands and thousands a month, distributing them all over the world.

It will go away. And as I say, we’re rounding the turn. We’re rounding the corner. It’s going away.

KRISTEN WELKER: OK. Former Vice President Biden, to you: How would you lead the country out of this crisis? You have two minutes, uninterrupted.

JOE BIDEN: Two hundred and twenty thousand Americans dead. If you hear nothing else I say tonight, hear this: Anyone who is responsible for not taking control, in fact, not saying I’m — “I take no responsibility,” initially — anyone who’s responsible for that many deaths should not remain as president of the United States of America.

We’re in a situation where there are a thousand deaths a day now. A thousand deaths a day. And there are over 70,000 new cases per day. Compared to what’s going on in Europe, as The New England Medical Journal said, they’re starting from a very low rate, we’re starting from a very high rate. The expectation is we’ll have another 200,000 Americans dead between now and the end of the year.

If we just wore these masks, the president’s own advisers have told him, we could save 100,000 lives. And we’re in a circumstance where the president thus far, and still, has no plan, no comprehensive plan.

AMY GOODMAN: Later in the debate, former Vice President Joe Biden criticized Trump for downplaying the pandemic.

JOE BIDEN: He did virtually nothing. And then he gets out of the hospital, and he talks about, “Oh, don’t worry. It’s all going to be over soon.” Come on. There’s not another serious scientist in the world who thinks it’s going to be over soon.

KRISTEN WELKER: President Trump, your reaction?

PRESIDENT DONALD TRUMP: I didn’t say “over soon.” I say we’re learning to live with it. We have no choice. … Ninety-nine-point-nine of young people recover. Ninety-nine percent of people recover. We have to recover. We can’t close up our nation. We have to open our school, and we can’t close up our nation, or you’re not going to have a nation. …

JOE BIDEN: He says that we’re — you know, we’re learning to live with it. People are learning to die with it. You folks home will have an empty chair at the kitchen table this morning. That man or wife going to bed tonight and reaching over to try to touch there, out of habit, where their wife or husband was, is gone. “Learning to live with it”? Come on. We’re dying with it, because he has never said — you see, you said, “It’s dangerous.” When’s the last time? Is it really dangerous still? Are we dangerous? You tell the people it’s dangerous now. And what should they do about the danger? And you say, “I take no responsibility.”

KRISTEN WELKER: Let me talk about your —

PRESIDENT DONALD TRUMP: Excuse me. I take full —

KRISTEN WELKER: Very quickly.

PRESIDENT DONALD TRUMP: I take full responsibility. It’s not my fault that it came here. It’s China’s fault.

AMY GOODMAN: President Trump and former Vice President Joe Biden at last night’s debate in Nashville.

To get response, we are joined by Dr. Ali Khan. He is an epidemiologist and the dean of the College of Public Health at the University of Nebraska Medical Center. He’s the former director of the CDC’s Office of Public Health Preparedness and Response, where he oversaw the Strategic National Stockpile. He’s joining us from Omaha, Nebraska. Nebraska is one of seven states now seeing a record level of COVID hospitalizations.

Dr. Ali Khan, welcome to Democracy Now! Can you respond to that last comment of President Trump’s, as he says he is not responsible for this?

DR. ALI KHAN: Well, good morning, Amy. And thank you very much for the opportunity to join you this morning.

Before I respond to the last comment, let’s step back a little bit and think how unusual this would be if we replaced COVID with polio or cholera or dysentery, that we would have a presidential debate and two different opposing political opinions about a disease that’s the third leading cause of death in America now, that was unknown 10 months ago, and we would be having a debate on whether or not it’s killing people and how it’s killing people. It’s unimaginable, if you just replace COVID with anything else. But that’s essentially what’s happening.

And what COVID has done very effectively is it has taken advantage of every splinter in our society, first, in terms of biologically — you know, elderly males, we know, are at higher risk — then social politically, economically. It’s extremely unfortunate, what’s going on in America, with over — actually, it’s 300,000 deaths right now.

AMY GOODMAN: Explain what you mean by 300,000 deaths.

DR. ALI KHAN: So, the 220,000 deaths that are reported are an underreport of deaths. And what you really need to look at, in addition to the actual individual cases that are reported, is excess deaths. And CDC has recently done a very nice analysis of looking at all excess deaths. So, these are people who would not have died. So, it’s not as if you — I often hear that, “Oh, they were elderly. They were going to die anyway.” That’s not true. These are individuals who would not have died this year, who are dead. And that’s over 300,000. And, yes, while absolutely there’s a lot more elderly people who have died, if you look relatively, there’s more deaths amongst the 25-to-44-year-olds, and there’s more deaths around Latinos, are more likely to die. So, yes, approximately 300,000 deaths in America, third leading cause of death, for a disease that was unknown in December.

AMY GOODMAN: Can you respond to the Columbia University report that just came out, the study, where researchers blasted the Trump administration over its disastrous handling of the pandemic? The authors write, “We estimate … at least 130,000 deaths … perhaps as many as 210,000 could have been avoided with earlier policy interventions and more robust federal coordination and leadership. Even with the dramatic recent appearance of new COVID-19 waves globally, the abject failures of U.S. government policies and crisis messaging persist.” Talk about what this means, what Trump did and didn’t do, as he talks about how well he dealt with the pandemic.

DR. ALI KHAN: So, Amy, this paper that came out of Columbia University by Dr. Irwin Redlener really puts estimates on how many people have unnecessarily died of this disease, and it tries to estimate those preventable deaths.

So, it’s always good — you know, I appreciate American exceptionalism, but you just need to go look at what’s going on in the rest of the world. China, zero deaths, their economy in the third quarter increased 4.9%, OK? And it’s not just China. New Zealand, Taiwan, Singapore, Uruguay, Uzbekistan — I can go on and on, all over the world, where countries where they had a robust public health strategy to decrease cases in their countries, and they are down to zero to no cases.

So, what this new paper says is, if we had just followed what we know the science is — so, the science, we know how to get rid of this disease: test, trace and isolate; community engagement, that’s masks, social distancing, handwashing; and excellent leadership at the national, state and local level. You put that controlled triad together, and the U.S. would not have had these preventable deaths.

And again, this is what happened in the past. I’m worried now about what’s happening in the future. We continue to see approximately 700 deaths, preventable deaths, every day in America because we still don’t have a containment strategy in America, we still don’t have that leadership, not just at the national level, state and local level, because public health is a local activity. So, where is that test, tracing and isolating happening? Where are those national and state and local mandates for masks, handwashing, social distancing? We know what it takes to get this disease under control. It is not a secret from a scientific standpoint.

AMY GOODMAN: This is the key point, Dr. Khan, that you say not just about the past here, but the future. As President Trump goes around the country now with his rallies, not clear when the last time was he met with the coronavirus task force, we’re talking about possibly as many people dying in the next few months as have died so far in this country, right? Over 200,000 people — you say 300,000 — since the beginning of the pandemic. What can be put in place right now? You were head of the National Stockpile. You worked at the CDC for years. Can you talk about, even if it is late, what President Trump needs to do, with invoking the Defense Production Act, still getting millions of tests and masks to people? He keeps saying anyone can get a test. It is just an absolute lie.

DR. ALI KHAN: So, you’re quite right, Amy. Even we can start today to prevent these 700 to a thousand deaths that are happening every day. We have the tools. We’ve always had the tools. It starts at the top, and then it cascades to the national, state, local, county, city, tribal, territorial level, which is, you need that unified leadership. As I said, just think about it. We’re arguing about a disease. This is great for COVID-19. It’s not good for us, right? That leadership, that we are going to contain this disease, we know what the science is to get this disease under control, we’re going to use evidence, we’re going to use metrics, we’re going to use data, and we’re going to drive down this disease.

The second thing we’re going to do — need to do is we need to ramp up test, trace and isolate. So, there is, obviously, gaps in testing in the United States, but there’s a lot of testing in the United States. But you have to link the testing with action. It’s not just about anybody who wants a test can get a test, because many people don’t even need a test. But the ones who do need a test, if they’re positive, have you made sure that they’re isolated? Have you found their contacts? Have you quarantined their contacts in a socially viable manner? And if you don’t do that, then why bother to test people, right?

And then the third thing is, at the — starting at the local level, where are mask mandates to make sure people are wearing masks, making sure they’re social distancing, whatever that looks like in that community based on what’s going on, and then making sure that they’re washing hands? I mean, we have the tools to get America back to work, to get all the kids back in school, and to get people, fans, back in stadiums. We have those tools right now, if we wanted to use them.

AMY GOODMAN: Quickly, if you could respond to what Trump is using as a pretext for not doing anything, and that is saying “herd immunity,” let the population get sick?

DR. ALI KHAN: Oh my gosh. That is the most unethical, disastrous approach that’s possible. So, herd immunity is a wonderful concept when we use vaccine to get herd immunity. However, herd immunity has never been used previously. It would be analogous of saying there’s an Ebola outbreak, and we go, “Oh, let’s go infect everybody so that it’s less disruptive in our society.”

So, herd immunity is the maximum death strategy, which is, you kill as many people as possible until potentially people are immune. Well, A, that’s so ludicrous, nobody has ever tried it before. B, it ignores the fact that you may have long-term sequela. So, I know people like to say 99% of people survive. Well, at a population level, unfortunately, 1% is still 3 million people in the U.S. But we do know that potentially a third of people, a quarter of people may have long-term heart, lung, kidney and brain damage. So, there’s still these long-term side effects that we’re not accounting for. And then, finally, if this disease really causes reinfections in four to six months, herd immunity can’t work. We get the cold every year. We have not yet had herd immunity to the cold virus, which is another type of coronavirus.

AMY GOODMAN: Which goes to —

DR. ALI KHAN: So, herd immunity is unethical.

AMY GOODMAN: Which goes to one of the first things President Trump said last night. He said, you know, he had COVID, and now he’s immune.

DR. ALI KHAN: And he may not — president or not, you know, if you get infected, you may not be immune forever. And we don’t know how long that immunity lasts. We know that there have been some cases of reinfection. So, that again says, how can you have herd immunity if you can get reinfected? So, correct, we hope that you’re protected for a very long period of time, but we need to get disease down to zero so that we don’t have infections in our community.

AMY GOODMAN: Before you go, I wanted to ask you about the Affordable Care Act. At one point in the 90-minute debate, Trump conflated Biden’s call for a government-run public option healthcare plan with a Medicare for All bill authored by Bernie Sanders.

PRESIDENT DONALD TRUMP: When he talks about a public option, he’s talking about destroying your Medicare, totally destroying —

JOE BIDEN: Wrong.

PRESIDENT DONALD TRUMP: — and destroying your Social Security. And this whole country will come down. You know, Bernie Sanders tried it in his state. …

KRISTEN WELKER: Vice President Biden, your response?

JOE BIDEN: He’s a very confused guy. He thinks he’s running against somebody else. He’s running against Joe Biden. I beat all those other people because I disagreed with them.

AMY GOODMAN: Dr. Ali Khan, I’m wondering if you could comment overall about Medicare for All. As President Trump went after socialized medicine, he didn’t talk about being at Walter Reed [hospital], where he dealt with his COVID-19. Isn’t that the epitome of socialized medicine, and very fine socialized medicine at that?

DR. ALI KHAN: Yeah, actually, quite — military medicine is quite excellent medicine, as is Medicare in the United States, which is an excellent healthcare system in the United States for the elderly and select others, that’s actually cost-effective. And again, American exceptionalism: If you look outside the U.S., numerous countries have figured out how to solve this universal access issue. And we need to solve that problem in America.

People like to talk about the new normal. I like to talk about the better normal, because there’s lots of things about the old normal I didn’t like. You know, institutional racism would be one of them. But, again, everybody needs to have access to healthcare in our better normal.

AMY GOODMAN: Dr. Ali Khan, I want to thank you for being with us, epidemiologist, dean of the College of Public Health at the University of Nebraska Medical Center, former director of the CDC’s Office of Public Health Preparedness and Response, where he oversaw the Strategic National Stockpile. He is in Nebraska, which is one of the seven states right now with record hospitalizations.

The original content of this program is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License. Please attribute legal copies of this work to democracynow.org. Some of the work(s) that this program incorporates, however, may be separately licensed. For further information or additional permissions, contact us.


No comments:

Post a Comment